Dr Chris Bailey
Dr Chris Bailey is director of development at the UK vaccine company, ImmunoBiology Ltd. During his earlier career at Beecham, Celltech and Medeva, Dr Bailey worked in new product development in the areas of vaccines, recombinant DNA products, gene therapies and small molecules. Dr Bailey has a PhD in microbial genetics from the University of Cambridge. He is based in Cambridge, UK.
Dr Gabriele Dallmann
Dr Gabriele Dallmann has more than 25 years of experience in drug development and regulatory strategy and currently directs the Munich-based regulatory consultancy Biopharma Excellence. She is also founder of the European Centre for Regulatory Affairs, based in Munich and Freiburg. Until 2005, she was in charge of the approval of antibody-containing products at the Paul-Ehrlich-Institute, Germany’s federal agency for vaccines and biomedicines. In this role, she was involved in the European approval of biopharmaceuticals at the European Medicines Agency.
Dr Miguel Forte
Dr Miguel Forte is chief executive of Zelluna Immunotherapy AS of Norway and a visiting professor at the Lisbon and Aveiro Universities in Portugal. He is also chair of the commercialisation committee of the International Society of Cellular Therapy. He holds an MD from the University of Lisbon, Portugal and a PhD in immunology from the University of Birmingham, UK.
Dr Thomas Lönngren
Dr Thomas Lönngren is the former executive director of the European Medicines Agency, having overseen the EMA’s growth from a small agency to one with both regional and global responsibilities. Prior to this, he was deputy director general at the Swedish Medical Products Agency. Dr Lönngren is currently director of Pharma Executive Consulting UK and a strategic advisor to NDA Group AB.
Professor Chris Mason
Professor Chris Mason, FRCS, is a co-founder and chief scientific officer of AvroBio Inc, a clinical-stage gene therapy company located in Cambridge, Massachusetts. He also holds the Chair of Cell and Gene Therapy in the Advanced Centre for Biochemical Engineering at University College London. Prof Mason is on a number of national and international committees, working groups and advisory boards enabling the clinical translation and commercialisation of cell and gene therapies.
Dr Edwin Moses
Dr Edwin Moses is chief executive of Ablnyx NV, part of Sanofi SA. He has over 25 years of experience in the life science and biotechnology sectors including board level positions, primarily as chairman, in over 15 companies. He was chairman of Ablynx from 2004 until 2013 and became CEO in 2006.
Dr Jean-Claude Muller
Dr Jean-Claude Muller is a special advisor to a number of international institutions, having previously been a senior vice president in research and development at Sanofi SA. At Sanofi, he was responsible for identifying strategic opportunities and potential breakthrough technologies. Dr Muller is a member of the board of directors of the Qiagen Suzhou Translational Medicine Corporation in China.
Dr John Purves
Dr John Purves is a life science consultant, having retired from the European Medicines Agency where he worked for 14 years, first as head of the biotechnology and biological products sector and most recently, as head of the sector for the quality of medicines. Prior to joining the EMA, Dr Purves was manager of the biotechnology and biological unit at the UK Medicines Control Agency, now the Medicines and Healthcare products Regulatory Agency.